ASCO 2023 | TIL 3.0 culture method for primary and metastatic uveal melanoma

Sapna Patel, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a single-center trial (NCT00338377) evaluating tumor-infiltrating lymphocytes (TIL) therapy for metastatic uveal melanoma, which is less responsive to immune checkpoint blockade. Successful ex vivo expansion of TIL was achieved in 34.8% of uveal melanoma tumors using the standard culture method (TIL 1.0), with higher rates in metastatic uveal melanoma compared to primary tumors. A new culture method (TIL 3.0) with CD3 and 41BB stimulation yielded better results, and durable responses were responded in two of nine patients with metastatic uveal melanoma. TIL harvest and expansion using the TIL 3.0 method showed promise for uveal melanoma treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.